NAD⁺ as a Signaling Molecule Modulating Metabolism

C. CANTÓ¹ AND J. AUWERX²

¹*Nestlé Institute of Health Sciences, CH-1015, Lausanne, Switzerland*

²*Ecole Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland*

Correspondence: admin.auwerx@epfl.ch

The ability of NAD⁺ to act as a metabolic cofactor and as a rate-limiting cosubstrate for many enzymes, particularly the sirtuins, has led to the identification of a pivotal role of NAD⁺ levels in the control of whole-body metabolic homeostasis. Bioavailability and compartmentalization of NAD⁺ have become highly relevant issues that we need to understand in order to elucidate how NAD⁺ acts both as a readout of the metabolic milieu and as an effector triggering appropriate cellular adaptations.

Early in the last century, four Nobel laureates, Sir Arthur Harden, Hans von Euler-Chelpin, Otto Warburg, and Arthur Komberg, contributed to the discovery of nicotinamide adenine dinucleotide (NAD⁺), the solution of its structure, and the definition of its key metabolic functions (Berger et al. 2004). In several cellular compartments, either oxidized or reduced NAD serves in transhydrogenase reactions catalyzed by various oxidoreductase enzymes (Houtkooper et al. 2010). It was only in the last decade, however, that the full extent of NAD⁺ function began to emerge with the identification of NAD⁺-consuming proteins, such as the sirtuin family of deacetylases, that in turn function as metabolic regulators (Houtkooper et al. 2010). Although not the only NAD⁺ consumers, sirtuins share the particularity of having a rather high K_m for NAD⁺ (Imai et al. 2000a; Smith et al. 2009; Houtkooper et al. 2010). Some sirtuins, such as the most widely studied SIRT1, have a K_m for NAD⁺ that lies within the range of physiological changes in intracellular NAD⁺ content. This suggested that, in some circumstances, NAD⁺ might be rate-limiting for the reaction catalyzed by the sirtuins and that, therefore, sirtuin activity might be modulated by NAD⁺ availability (Imai et al. 2000b). This hypothesis was rapidly embraced by the scientific community and led to the concept of sirtuins being “metabolic sensors” whose activity was coupled to metabolic shifts manifested as changes in the NAD⁺/NADH redox state. Although there are still caveats in this hypothesis, it highlighted the possible nature of NAD⁺ as not just a coenzyme, but also a messenger that can modulate cellular transcriptional responses and metabolic adaptations.

The coenzymatic activity of NAD⁺, together with the tight regulation of its biosynthesis and bioavailability, positions it well to act as a metabolic monitoring system. To be true metabolic sensors, however, NAD⁺-consuming enzymes must respond to physiological changes in NAD⁺ levels. In this review, we try to assemble the

evidence indicating that modulating NAD⁺ levels might be a valuable strategy to drive metabolic adaptations and influence sirtuin activity.

SIRTUINS AS NAD⁺ SENSORS

The Sirtuin Family of Deacetylases

Sirtuins are a family of NAD⁺-dependent protein deacetylases that are similar to the yeast silent information regulator 2 (Sir2). Most sirtuins remove acetyl modifications of lysine residues on histones and other proteins in a reaction that, unlike that catalyzed by type I and type II histone deacetylases (HDACs), consumes NAD⁺, releasing nicotinamide (NAM), *O*-acetyl ADP ribose, and the deacetylated substrate (Houtkooper et al. 2010).

There are seven members in the mammalian family of sirtuin enzymes, named SIRT1–7 (Dali-Youcef et al. 2007; Michan and Sinclair 2007). They are ubiquitously expressed and share a conserved catalytic core of 275 amino acids. The diversity of sirtuin genes in mammals is associated with a specialization of their function and cellular localization. In line with the role of yeast Sir2 in the regulation of chromatin structure and gene expression, SIRT1, SIRT6, and SIRT7 are localized in the nuclei of cells (Michishita et al. 2005). SIRT2 is mainly localized in the cytoplasm (Michishita et al. 2005), even though it can also regulate gene expression by deacetylating transcriptional regulators that display nucleocytoplasmic shuttling (Jing et al. 2007) and influences chromatin compaction upon disassembly of the cell nucleus during mitosis (Vaquero et al. 2006). The remaining sirtuin members—SIRT3, SIRT4, and SIRT5—are mitochondrial proteins (Onyango et al. 2002; Schwer et al. 2002; Michishita et al. 2005). Additional complexity is added by the fact that some sirtuins, such as SIRT1, can shuttle between compartments in response to diverse stimuli

(Tanno et al. 2007). The existence of different sirtuins in a similar compartment might also be explained because not all members show similar enzymatic activity. In this way, SIRT1 acts exclusively as a deacetylase (Vaziri et al. 2001; North et al. 2003), whereas SIRT2, SIRT3, SIRT4, and SIRT6 may also act as mono-ADP-ribosyl transferases (North et al. 2003; Liszt et al. 2005; Shi et al. 2005; Haigis et al. 2006). Interestingly, very recently SIRT5 was described not only as a deacetylase but also as a desuccinylase but demalonyase (Du et al. 2011). In the case of SIRT7, no clear enzymatic activity has been reported to date, although it has been proposed to act as a deacetylase enzyme (Vakhrusheva et al. 2008).

In the last decade, sirtuins have come into the spotlight owing to their ability to modulate metabolic function and life span in lower organisms. In general, sirtuins become active in situations of nutritional/energetic deficit and prompt whole-body metabolic adaptations aimed to improve metabolic efficiency and enhance the use of noncarbohydrate energy sources. For example, SIRT1 activation enhances lipid oxidation and mitochondrial biogenesis, whereas SIRT3 is a key regulator of acetate, ketone body, and fatty acid metabolism by deacetylating mitochondrial proteins. Another sirtuin, SIRT6, negatively regulates glycolysis. For an extended view on the function of the different sirtuins, we refer the reader to some of the reviews that cover that topic (Yamamoto et al. 2007; Houtkooper et al. 2010; Verdin et al. 2010). Diverse genetic and pharmacological approaches suggest that sirtuin activation might be useful to manage metabolic and age-related diseases, generally characterized by decreased mitochondrial function (Baur et al. 2006; Lagouge et al. 2006; Herranz and Serrano 2010). The identification of sirtuin-activating compounds has, however, led to controversial results, because several of them might act through indirect means (Pacholec et al. 2010). The particularity that sirtuins require NAD^+ for their enzymatic reaction raised the interesting possibility of modulating sirtuin activity by altering NAD^+ metabolism.

Do Sirtuins Act as NAD^+ Sensors?

The concept that sirtuins could act as NAD^+ sensors has its roots in two observations in yeast: first, that the activity of Sir2 is NAD^+ -dependent (Imai et al. 2000a) and second, that Sir2 could play a key role in mediating the effects of glucose restriction on yeast replicative life span (Kaeberlein et al. 1999). Connecting the dots, the Guarente laboratory proposed that the metabolic changes induced by calorie or glucose restriction, mainly manifested as a proportionally higher prominence of mitochondrial respiration, may lead to higher NAD^+ levels, inducing Sir2 activation (Lin et al. 2002). The activation of Sir2 would then allow the cell to properly adapt to nutrient scarcity and promote enhanced life span.

A few aspects of the above hypothesis are still controversial (for review, see Cantó and Auwerx 2009, 2012) and merit some scrutiny. Among them is whether sirtuin activity can really respond to changes in intracellular NAD^+ levels. One premise, at least, must be met in that

context, that is, that the K_m of the sirtuins for NAD^+ falls into the physiological range of NAD^+ bioavailability. Direct experimental evidence supporting this point is, in some cases, however, preliminary or absent.

An initial difficulty in establishing whether the K_m of the sirtuins is within the physiological range of NAD^+ bioavailability resides in the difficulty in properly quantifying NAD^+ content itself. Through different methodologies, the intracellular NAD^+ concentrations have been estimated to be between 0.2 and 0.5 mM (for reviews, see Sauve et al. 2006; Houtkooper et al. 2010). These levels, however, do not discriminate between free and protein-bound NAD^+ . Similarly, this approximation does not take into account the existence of cellular compartmentalization of NAD^+ . For example, it has been postulated that up to 75% of total intracellular NAD^+ in heart and myocytes would be in the mitochondrial compartment (Di Lisa and Ziegler 2001). This led to the hypothesis that mitochondrial NAD^+ levels are much higher than in other compartments. However, the evidence supporting such a statement is weak at best. For example, most NAD^+ is concentrated in the cytosol in other cell types, such as hepatocytes (Tischler et al. 1977). In human erythrocytes, which have no mitochondria, NAD^+ contents average at 350 μM (Yamada et al. 2006), which is similar to the NAD^+ content measured in mitochondria-containing cell types. Mitochondrial NAD^+ concentrations have rarely been accurately determined until recently, when they were established at $\sim 250 \mu\text{M}$ in cultured HEK293 cells (Yang et al. 2007a). In the same study, total NAD^+ concentrations in HEK293 cells were estimated at $\sim 365 \mu\text{M}$ (Yang et al. 2007a), suggesting that NAD^+ levels are more evenly distributed in cells than originally expected. Furthermore, accurate measurements of NAD^+ in other specific cellular compartments are missing, although preliminary data indicate that free unbound NAD^+ concentration in the nucleus might be, at least, $\sim 70 \mu\text{M}$ (Fjeld et al. 2003). Despite the fact that current data suggest that NAD^+ levels might be evenly distributed in the cell, it is important to underscore that we still have fragmentary knowledge on the real bioavailability of NAD^+ for sirtuins.

A second major point is that the K_m for NAD^+ of different sirtuins is still far from established. In the case of SIRT1, the K_m is generally accepted to be in the 100–200 μM range, even though values between 50 and 500 μM have been reported (Wood et al. 2004; Sauve et al. 2006; Smith et al. 2009; Houtkooper et al. 2010; Pacholec et al. 2010). For SIRT2, the K_m for NAD^+ has also been set at $\sim 100 \mu\text{M}$ (Smith et al. 2009). For the mitochondrial sirtuins, the K_m of SIRT3 for NAD^+ , $\sim 300 \mu\text{M}$ (Jin et al. 2009), seems to be higher than that of SIRT5 (100 μM) in vitro (Nakagawa et al. 2009). For the other sirtuins, the values are yet to be examined. In general, the K_m of sirtuins for NAD^+ seems to fall into the physiological range of NAD^+ levels, suggesting that NAD^+ availability might in fact be rate-limiting for the sirtuin reaction. Importantly, the physiological concentrations of intracellular NAD^+ rarely fluctuate more than twofold (Rodgers et al. 2005; Chen et al. 2008; Fulco

et al. 2008; Cantó et al. 2009), which is a probable range to impact sirtuin activity. Furthermore, the complete understanding of NAD⁺ partitioning and availability will be crucial to fully determine the range of NAD⁺ fluctuations that is required to influence the activity of different sirtuins.

STRATEGIES AIMED TO MODULATE SIRTUIN ACTIVITY THROUGH NAD⁺

NAD⁺ Salvage and Biosynthesis

One strategy to test how enhancing NAD⁺ levels regulates sirtuin activity consists of boosting NAD⁺ synthesis by supplementation with NAD⁺ precursors. Different precursors can induce NAD⁺ synthesis. The primary *de novo* synthesis of NAD⁺ generally initiates from tryptophan (Rongvaux et al. 2003). Nicotinic acid (NA) is another NAD⁺ precursor and it is transformed into NAD⁺ through the Preiss–Handler pathway, therefore converging with the synthesis of NAD⁺ from tryptophan. However, it is assumed that perhaps the principle source of NAD⁺ comes from salvage pathways from other adenine nucleotide metabolites (Rongvaux et al. 2003). The main NAD⁺ precursors that funnel through the salvage pathways are NAM and the more recently described nicotinamide riboside (NR). NAM generates NAD⁺ through a completely independent pathway, in which the rate-limiting enzyme nicotinamide phosphoribosyltransferase (Nampt), transforms NAM into nicotinamide mononucleotide (NMN), which in its turn is converted into NAD⁺ by the NMN adenylyltransferase (NMNAT) (Revollo et al. 2004). Finally, NR is phosphorylated upon its entry in the cell by the NR kinases (NRKs), generating NMN, which is then converted to NAD⁺ by NMNAT (Bieganski and Brenner 2004).

Few studies to date have described how these precursors impact NAD⁺ levels and in particular affect sirtuin activity. Both NA and NAM can lead to higher NAD⁺ levels, even though the effects might be tissue-specific. For example, NAM seems to be a more stable NAD⁺ precursor in the liver upon intraperitoneal injection (Collins and Chaykin 1972), but NA seems to be more efficient in the kidney (Hara et al. 2007). Cell-based experiments also support the existence of cell-specific differences. For example, in NIH3T3 cells concentrations of up to 5 mM NAM did not increase intracellular NAD⁺ levels (Revollo et al. 2004). NAM also proved to be a relatively inefficient NAD⁺ precursor in HEK293 cells, but a 5 mM concentration doubled intracellular NAD⁺ (Hara et al. 2007). In the latter study, it was also proven that in human cells, NA seems to be a more efficient NAD⁺ precursor than NAM, because concentrations as low as 20 μ M were enough to double NAD⁺ content. The cell/tissue-specific efficiencies of distinct NAD⁺ precursors might be related to the differential expression of the rate-limiting enzymes in their respective metabolic pathways. In this way, the metabolism of NA into NAD⁺ is rate-limited by the NA phosphoribosyltransferase (NAPT), which is highly expressed in some tissues, such as liver or kidney (Hara

et al. 2007). A reduction in NAPT activity in HEK293 cells does not affect basal NAD⁺ levels but impairs NA-induced NAD⁺ accumulation (Hara et al. 2007). To date, however, no clear link between NA supplementation and sirtuin activity has been made.

In the case of NAM, it is well known that, in mammals, Nampt rate-limits the salvage of NAD⁺ from NAM (Revollo et al. 2004). Nampt is unevenly distributed among tissues. For example, its expression is high in brown adipose tissue, liver, and kidney, whereas its levels are low in white adipose tissue or skeletal muscle and apparently absent in brain and pancreas (Revollo et al. 2007). These findings suggest that, as happened with NA, the activity of Nampt-mediated NAD⁺ biosynthesis might vary widely among different tissues. The modulation of Nampt activity has a clear impact on NAD⁺ levels in virtually any mammalian cell tested to date (for examples, see van der Veer et al. 2005; Fulco et al. 2008; Rongvaux et al. 2008; Pittelli et al. 2010). In most of these cases, the alterations in NAD⁺ levels promoted by differential Nampt activity were associated with changes in SIRT1 activity (van der Veer et al. 2005, 2007; Revollo et al. 2007; Fulco et al. 2008). A complication from these experiments is that the influence that Nampt exerts on SIRT1 activity may not derive only from altering NAD⁺ availability, but also from NAM clearance. The reaction catalyzed by SIRT1 and, in general, all sirtuins, is efficiently inhibited in a noncompetitive fashion by NAM (Bitterman et al. 2002). In this way, the possible accumulation of NAM upon a reduction in Nampt activity might by itself be enough to reduce sirtuin activity. As in the case of NAD⁺, the current methodologies to measure NAM are rather limited and most studies to date do not report NAM levels. Different from NAD⁺, NAM can freely diffuse through membranes (van Roermund et al. 1995), making it even more challenging to establish its bioavailability.

The effects of NR, the more recently discovered precursor, also remain largely unknown. Although there is already evidence that NR can increase intracellular NAD⁺ in mammalian cells (Yang et al. 2007b), whether this can influence sirtuin activity is still unknown. However, several lines of evidence established in yeast suggest that this might in fact be the case. Exogenous supplementation of NR to yeast enhanced Sir2-dependent repression of recombination, improved gene silencing, and extended replicative life span (Belenky et al. 2007). All of these actions were completely dependent on NAD⁺ synthesis (Belenky et al. 2007). Whereas genetic manipulations aimed to alter the enzymatic capacity of the NAD⁺ salvage metabolism have been known for some time to impact on life span (Anderson et al. 2002, 2003), the experiments using NR constitute the first solid evidence that enhancing NAD⁺ bioavailability via NAD⁺ precursor supplementation can also enhance sirtuin activity and prompt beneficial metabolic and longevity actions. Furthermore, the discovery that NR is present in milk poses an interesting opportunity for food-based preventive or therapeutic interventions in NAD⁺-dependent metabolism.

In contrast to our poor knowledge of how NR supplementation acts in mammals, both NA and NAM have been used for a long time in a clinical setting. Niacin, basically composed of NA and NAM, has been widely used as an efficient way to overcome situations of dietary tryptophan deficits, which when untreated lead to NAD⁺ deficiency and pellagra (Sauve 2008). Furthermore, niacin is used to treat hypercholesterolemia, because it efficiently decreases very-low-density lipoprotein synthesis, and lowers low-density lipoprotein cholesterol levels, while concurrently increasing high-density lipoprotein cholesterol (Altschul et al. 1955; Karpe and Frayn 2004). The use of niacin as a lipid-lowering agent might also result in beneficial effects on coronary disease and type 2 diabetes mellitus. Many of these beneficial actions of niacin in mice and humans—as well as undesired effects, such as spontaneous flushing—have been attributed to the activation of a putative NA-activated G-coupled receptor, GPR109A (Tunaru et al. 2003; Benyo et al. 2005). Whereas the role of GPR109A in mediating niacin-induced flushing is rather well established (Benyo et al. 2005), the hypothesis that the therapeutic efficacy of niacin is mediated by GPR109A activation needs to be revisited. First, even if GPR109A has a relatively high affinity for NA (EC₅₀ ~100 nM), such levels of NA are rarely found in plasma unless pharmacologically primed (Kirkland 2009), indicating that the activation of GRP109A by NA is probably fortuitous, but not biologically relevant in the basal state. Second, many of the beneficial effects of niacin, such as the lipid-lowering effects (Kamanna and Kashyap 2008), take place at higher concentrations than are required for GPR109A activation, but which lead to intracellular NAD⁺ accumulation (Jackson et al. 1995). A third issue is that the specific tissue distribution of GRP109A receptors makes it very difficult to explain how niacin can perform some of its actions in particular tissues, especially in liver cholesterol homeostasis (Li et al. 2010). It is therefore tempting to speculate that some of these effects might be achieved through an NAD⁺-induced activation of sirtuins and the consequent deacetylation of, for example, SIRT1 targets, such as the peroxisome-proliferator-activated receptor coactivator 1 family of transcriptional coactivators (Rodgers et al. 2005; Kelly et al. 2009) and members of the sterol regulatory element-binding protein (SREBP) transcription factor family, which act as critical regulators of fatty acid, lipid, and sterol homeostasis in eukaryotes (Walker et al. 2010). An additional appealing possibility to explain the effects of niacin involves the fact that it leads to adiponectin release from white adipose tissue (Vaccari et al. 2007; Westphal et al. 2007). Adiponectin then activates AMP-activated protein kinase (AMPK) in muscle and liver tissues and can in this way enhance NAD⁺ content and SIRT1 activity (Cantó et al. 2009; Iwabu et al. 2010).

NAD⁺ Consumption

Another attractive strategy to modulate NAD⁺ levels and favor sirtuin activity resides in the modulation of the

activity of nonsirtuin NAD⁺-consuming enzymes. There are two major families of alternative NAD⁺ consumers: the poly(ADP)-ribosyl polymerases (PARPs) and the cADP-ribose synthases (CD38 and CD157; Houtkooper et al. 2010).

PARPs use NAD⁺ as a substrate for a cellular process in which the ADP-ribose moiety is not transferred to an acetyl group, as happens with sirtuins, but is used to build ADP-ribosyl polymers onto acceptor proteins (Chambon et al. 1963; Krishnakumar and Kraus 2010). PARP activity is dramatically enhanced upon DNA damage and oxidative stress. Most PARP activity upon oxidative damage is driven by PARP-1, except for a residual 5%–10%, which is likely to be accounted for by PARP-2 (Shieh et al. 1998; Ame et al. 1999). Overactivation of PARP-1 upon oxidative damage rapidly depletes intracellular NAD⁺ levels (Goodwin et al. 1978; Skidmore et al. 1979). In line with the hypothesis that NAD⁺ might be rate-limiting for SIRT1 action, SIRT1 activity is down-regulated in situations of PARP-1 activation (Pillai et al. 2005; Bai et al. 2011b). Interestingly, SIRT1 does not seem to be directly regulated by PARP activity (Bai et al. 2011a,b). These observations indicate that PARP-1 and SIRT1 activity are connected through competition for a limited NAD⁺ pool. Importantly, PARP-1 has a very low *K_m* (~20 μM) and a relatively high *V_{max}* for NAD⁺ (Mendoza-Alvarez and Alvarez-Gonzalez 1993), indicating that PARP-1 activity might limit SIRT1 action, but not the other way around.

In a recent report, our laboratory demonstrated how a down-regulation of PARP-1 activity favors SIRT1 activation (Bai et al. 2011b). Genetic and pharmacological approaches aiming to abrogate PARP-1 activity lead to higher NAD⁺ levels. Whereas PARP activity is generally accepted to be rather low in the basal state, recent evidence indicates that it naturally fluctuates in a circadian fashion (Asher et al. 2010). In line with the existence of basal PARP activity, inhibition of its activity gradually leads to a buildup of NAD⁺ levels in cultured cells (Bai et al. 2011b). Similarly, tissues from PARP-1 knockout mice display higher NAD⁺ levels (Bai et al. 2011b), roughly twofold higher than those of wild-type littermates. The increase in NAD⁺ levels promoted by PARP inhibition leads, both in vivo and in vitro, to higher SIRT1 activity (Bai et al. 2011b). In this way, PARP inhibition is associated with induction of the expression of genes involved in mitochondrial and lipid oxidation in a SIRT1-dependent manner. From a physiological perspective, the better metabolic fitness derived from SIRT1 activation in situations of low PARP-1 activity offers the mice protection against the onset of metabolic disease in the context of diet-induced obesity (Bai et al. 2011b). Furthermore, this opens up the perspective on a possible role of PARP in ageing, because SIRT1 activity has been positively associated with the beneficial effects of calorie restriction on health and life span (Cantó and Auwerx 2011). Therefore, PARP inhibition could constitute a useful tool to activate SIRT1 and mimic the calorie-restricted state. In line with this hypothesis, it was recently reported that PARP activity is higher in aged tissues,

leading to decreased SIRT1 activity (Braidy et al. 2011; L Mouchiroud, C Cantó, and J Auwerx, unpubl.). Further confirming the hypothesis that higher PARP-1 activity might be detrimental for SIRT1 activity and global metabolism was the fact that mice expressing an additional copy of the human PARP-1 had a reduced median life span, impaired glucose metabolism, and higher susceptibility to age-related diseases (Mangerich et al. 2010).

Interestingly, the NAD⁺-boosting effects of PARP inhibition enhance the activity of SIRT1 (nuclear), but not that of SIRT2 (cytoplasmic) or SIRT3 (mitochondrial) (Bai et al. 2011b). The major difference between these three sirtuins is their subcellular localization, suggesting the existence of compartment-specific NAD⁺ pools in the cell. This was nicely illustrated by the Sinclair laboratory, showing the existence of independently regulated NAD⁺ pools and that depletion of the cytosolic/nuclear pools can happen while mitochondrial pools remain intact (Yang et al. 2007a).

Another small family of NAD⁺ consumers are the cADP-ribose synthases, CD38, and the less characterized CD157. CD38 and CD157 are multifunctional enzymes that use NAD⁺ as a substrate to generate second messengers, such as cADP-ribose, which regulates calcium mobilization (Lee 2006). Most studies on how cADP-ribose synthases impact NAD⁺ levels and SIRT1 activity have been done with CD38. As happened with PARP-1, CD38 displays a very low K_m for NAD⁺ (15–25 μ M) (Cakir-Kiefer et al. 2001). Importantly, the stoichiometry of the reaction catalyzed by CD38 involves massive amounts of NAD⁺, ~100 molecules, to yield a single cADP-ribose (Dousa et al. 1996). Therefore, even a small amount of CD38 activity might have a dramatic influence on intracellular NAD⁺ metabolism. Strikingly, the enzymatic activity of CD38 is located outside of the plasma membrane (De Flora et al. 1997), which makes it challenging to determine the accessibility of NAD⁺ for this enzyme, because NAD⁺ is only present in minute quantities outside the cell (O'Reilly and Niven 2003). It was recently reported that CD38 might also be present in the nuclear compartment, which would then open a role for CD38 as a main intracellular NAD⁺ consumer (Aksoy et al. 2006a). This role of CD38 as an intracellular NADase was proven to be correct when mice lacking CD38 displayed a 30-fold increase in intracellular NAD⁺ levels (Aksoy et al. 2006b). This increase is far superior compared with the approximately twofold increases generally observed in most genetic (PARP-1 deletion), pharmacological (NAD⁺ precursors), and physiological interventions (fasting, calorie restriction) aimed to enhance NAD⁺ content. Given such an increase in NAD⁺, it would be expected that CD38 deletion might have a major impact on sirtuin activity. It was therefore reassuring to see how, as happened with PARP-1, CD38 deletion significantly activated SIRT1 and prompted similar clinical phenotypes to those expected for SIRT1 activation, including protection against diet-induced obesity and a robust deacetylation of SIRT1 targets (Aksoy et al. 2006a). Given the nuclear and plasma membrane localization of CD38, it will be interesting to evaluate in the future whether the increase

in NAD⁺ is homogeneous between compartments and whether all sirtuins are similarly affected.

CONCLUSIONS AND FUTURE PERSPECTIVES

Different strategies aiming to modify the intracellular NAD⁺ content have provided correlative evidence that higher NAD⁺ bioavailability is matched by higher sirtuin activity. However, this assertion still needs some further work. For example, most studies have focused their attention on mammalian SIRT1. The mammalian sirtuin family, however, comprises seven distinct members distributed in different cellular compartments. It will be key to elucidate whether the different physiological, pharmacological, and genetic manipulations that boost NAD⁺ availability lead to a homogenous increase in the activity of all sirtuin enzymes or whether only a few family members are affected, owing either to their different enzymatic kinetics for NAD⁺ or to the probable compartmentalization of the modulation in NAD⁺ levels. This latter possibility could be highly relevant to designing therapeutic strategies aimed at selectively activating specific sirtuin members. It will therefore be crucial to improve the currently available techniques used to evaluate intracellular NAD⁺ content and determine sirtuin-specific activity. We will also have to devote efforts to fully understanding how the activity of the different sirtuins is affected by other factors, from transcriptional and translational to posttranslational processes, and how this interrelates with effects on NAD⁺ kinetics/compartmentalization. A good example of the complexity of sirtuin biology can be found in the regulation of PGC-1 α deacetylation by SIRT1. AMPK-induced PGC-1 α phosphorylation facilitates its subsequent deacetylation by SIRT1 (Jager et al. 2007; Cantó et al. 2009), indicating that the activity of sirtuins on certain substrates might be coupled not only to NAD⁺ availability, but also to the accessibility of the target, which is determined by another posttranslational modification. Another example can be found in how SIRT1 function is influenced by the ability of different molecular coactivators (e.g., GCN5) of corepressor (e.g., NCoR1 and HDAC3) complexes to interact with SIRT1 or SIRT1 targets (Picard et al. 2004; Gerhart-Hines et al. 2007).

Despite these shortcomings, a steadily increasing amount of evidence indicates that the pharmacological modulation of NAD⁺ levels could be a valid strategy to manage metabolic and age-related diseases. PARP inhibitors have been reported to be an attractive tool to enhance oxidative metabolism and promote mitochondrial biogenesis (Bai et al. 2011b). Similarly, the striking ability of NR to enhance yeast life span (Belenky et al. 2007) warrants future study to further define the mechanisms through which NR and other NAD precursors might impact mammalian metabolism. It will also be important to evaluate whether NR might be a valid substitute to avoid the undesirable side effects of other NAD⁺ precursors, such as NA and NAM, when used as lipid-lowering compounds.

ACKNOWLEDGMENTS

The work in the laboratory of the authors was supported by grants of the Ecole Polytechnique Fédérale de Lausanne, Swiss National Science Foundation, National Institutes of Health (DK59820), the European Research Council Ideas Programme (sirtuins; ERC-2008-AdG23118), and the Velux Foundation. J.A. is the Nestlé Chair in Energy Metabolism. The authors thank all the members of the Auwerx Laboratory for inspiring discussions and declare no conflict of interests.

REFERENCES

- Aksoy P, Escande C, White TA, Thompson M, Soares S, Benesh JC, Chini EN. 2006a. Regulation of SIRT1 mediated NAD dependent deacetylation: A novel role for the multifunctional enzyme CD38. *Biochem Biophys Res Commun* **349**: 353–359.
- Aksoy P, White TA, Thompson M, Chini EN. 2006b. Regulation of intracellular levels of NAD: A novel role for CD38. *Biochem Biophys Res Commun* **345**: 1386–1392.
- Altschul R, Hoffer A, Stephen JD. 1955. Influence of nicotinic acid on serum cholesterol in man. *Arch Biochem Biophys* **54**: 558–559.
- Ame JC, Rolli V, Schreiber V, Niedergang C, Apiou F, Decker P, Muller S, Hoyer T, Menissier-de Murcia J, de Murcia G. 1999. PARP-2, a novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase. *J Biol Chem* **274**: 17860–17868.
- Anderson RM, Bitterman KJ, Wood JG, Medvedik O, Cohen H, Lin SS, Manchester JK, Gordon JI, Sinclair DA. 2002. Manipulation of a nuclear NAD⁺ salvage pathway delays aging without altering steady-state NAD⁺ levels. *J Biol Chem* **277**: 18881–18890.
- Anderson RM, Bitterman KJ, Wood JG, Medvedik O, Sinclair DA. 2003. Nicotinamide and PNC1 govern lifespan extension by calorie restriction in *Saccharomyces cerevisiae*. *Nature* **423**: 181–185.
- Asher G, Reinke H, Altmeyer M, Gutierrez-Arcelus M, Hottiger MO, Schibler U. 2010. Poly(ADP-ribose) polymerase 1 participates in the phase entrainment of circadian clocks to feeding. *Cell* **142**: 943–953.
- Bai P, Cantó C, Brunyanszki A, Huber A, Szanto M, Cen Y, Yamamoto H, Houten SM, Kiss B, Oudart H, et al. 2011a. PARP-2 regulates SIRT1 expression and whole-body energy expenditure. *Cell Metab* **13**: 450–460.
- Bai P, Cantó C, Oudart H, Brunyanszki A, Cen Y, Thomas C, Yamamoto H, Huber A, Kiss B, Houtkooper RH, et al. 2011b. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. *Cell Metab* **13**: 461–468.
- Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, et al. 2006. Resveratrol improves health and survival of mice on a high-calorie diet. *Nature* **444**: 337–342.
- Belenky P, Racette FG, Bogan KL, McClure JM, Smith JS, Brenner C. 2007. Nicotinamide riboside promotes Sir2 silencing and extends lifespan via Nrk and Urh1/Pnp1/Meu1 pathways to NAD⁺. *Cell* **129**: 473–484.
- Benyo Z, Gille A, Kero J, Csiky M, Suchankova MC, Nusing RM, Moers A, Pfeiffer K, Offermanns S. 2005. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. *J Clin Invest* **115**: 3634–3640.
- Berger F, Ramirez-Hernandez MH, Ziegler M. 2004. The new life of a centenarian: Signalling functions of NAD(P). *Trends Biochem Sci* **29**: 111–118.
- Bieganowski P, Brenner C. 2004. Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD⁺ in fungi and humans. *Cell* **117**: 495–502.
- Bitterman KJ, Anderson RM, Cohen HY, Latorre-Esteves M, Sinclair DA. 2002. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. *J Biol Chem* **277**: 45099–45107.
- Briday N, Guillemin GJ, Mansour H, Chan-Ling T, Poljak A, Grant R. 2011. Age related changes in NAD⁺ metabolism oxidative stress and sirt1 activity in Wistar rats. *PLoS One* **6**: e19194.
- Cakir-Kiefer C, Muller-Steffner H, Oppenheimer N, Schuber F. 2001. Kinetic competence of the cADP-ribose-CD38 complex as an intermediate in the CD38/NAD⁺ glycohydrolase-catalysed reactions: Implication for CD38 signalling. *Biochem J* **358**: 399–406.
- Cantó C, Auwerx J. 2009. Caloric restriction, SIRT1 and longevity. *Trends Endocrinol Metab* **20**: 325–331.
- Cantó C, Auwerx J. 2011. Interference between PARPs and SIRT1: A novel approach to healthy ageing? *Ageing (Albany NY)* **3**: 543–547.
- Cantó C, Auwerx J. 2012. Targeting sirtuin 1 to improve metabolism: All you need is NAD⁺? *Pharmacol Rev* **64**: 166–187.
- Cantó C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, Elliott PJ, Puigserver P, Auwerx J. 2009. AMPK regulates energy expenditure by modulating NAD⁺ metabolism and SIRT1 activity. *Nature* **458**: 1056–1060.
- Chambon P, Weill JD, Mandel P. 1963. Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. *Biochem Biophys Res Commun* **11**: 39–43.
- Chen D, Bruno J, Easlon E, Lin SJ, Cheng HL, Alt FW, Guarente L. 2008. Tissue-specific regulation of SIRT1 by calorie restriction. *Genes Dev* **22**: 1753–1757.
- Collins PB, Chaykin S. 1972. The management of nicotinamide and nicotinic acid in the mouse. *J Biol Chem* **247**: 778–783.
- Dali-Youcef N, Lagouge M, Froelich S, Koehl C, Schoonjans K, Auwerx J. 2007. Sirtuins: The “magnificent seven”, function, metabolism and longevity. *Ann Med* **39**: 335–345.
- De Flora A, Guida L, Franco L, Zocchi E. 1997. The CD38/cyclic ADP-ribose system: A topological paradox. *Int J Biochem Cell Biol* **29**: 1149–1166.
- Di Lisa F, Ziegler M. 2001. Pathophysiological relevance of mitochondria in NAD(+) metabolism. *FEBS Lett* **492**: 4–8.
- Dousa TP, Chini EN, Beers KW. 1996. Adenine nucleotide diphosphates: Emerging second messengers acting via intracellular Ca²⁺ release. *Am J Physiol* **271**: C1007–C1024.
- Du J, Zhou Y, Su X, Yu JJ, Khan S, Jiang H, Kim J, Woo J, Kim JH, Choi BH, et al. 2011. Sirt5 is an NAD-dependent protein lysine demalonylase and desuccinylase. *Science* **334**: 806–809.
- Fjeld CC, Birdsong WT, Goodman RH. 2003. Differential binding of NAD⁺ and NADH allows the transcriptional corepressor carboxyl-terminal binding protein to serve as a metabolic sensor. *Proc Natl Acad Sci* **100**: 9202–9207.
- Fulco M, Cen Y, Zhao P, Hoffman EP, McBurney MW, Sauve AA, Sartorelli V. 2008. Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt. *Dev Cell* **14**: 661–673.
- Gerhart-Hines Z, Rodgers JT, Bare O, Lerin C, Kim SH, Mostoslavsky R, Alt FW, Wu Z, Puigserver P. 2007. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1α. *EMBO J* **26**: 1913–1923.
- Goodwin PM, Lewis PJ, Davies MI, Skidmore CJ, Shall S. 1978. The effect of gamma radiation and neocarzinostatin on NAD and ATP levels in mouse leukaemia cells. *Biochim Biophys Acta* **543**: 576–582.
- Haigis MC, Mostoslavsky R, Haigis KM, Fahie K, Christodoulou DC, Murphy AJ, Valenzuela DM, Yancopoulos GD, Karow M, Blander G, et al. 2006. SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic β cells. *Cell* **126**: 941–954.
- Hara N, Yamada K, Shibata T, Osago H, Hashimoto T, Tsuchiya M. 2007. Elevation of cellular NAD levels by nicotinic acid and involvement of nicotinic acid phosphoribosyltransferase in human cells. *J Biol Chem* **282**: 24574–24582.
- Herranz D, Serrano M. 2010. Impact of Sirt1 on mammalian aging. *Ageing (Albany NY)* **2**: 315–316.

- Houtkooper RH, Cantó C, Wanders RJ, Auwerx J. 2010. The secret life of NAD⁺: An old metabolite controlling new metabolic signaling pathways. *Endocr Rev* **31**: 194–223.
- Imai S, Armstrong CM, Kaerberlein M, Guarente L. 2000a. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. *Nature* **403**: 795–800.
- Imai S, Johnson FB, Marciniak RA, McVey M, Park PU, Guarente L. 2000b. Sir2: An NAD-dependent histone deacetylase that connects chromatin silencing, metabolism, and aging. *Cold Spring Harb Symp Quant Biol* **65**: 297–302.
- Iwabu M, Yamauchi T, Okada-Iwabu M, Sato K, Nakagawa T, Funata M, Yamaguchi M, Namiki S, Nakayama R, Tabata M, et al. 2010. Adiponectin and AdipoR1 regulate PGC-1 α and mitochondria by Ca(2+) and AMPK/SIRT1. *Nature* **464**: 1313–1319.
- Jackson TM, Rawling JM, Roebuck BD, Kirkland JB. 1995. Large supplements of nicotinic acid and nicotinamide increase tissue NAD⁺ and poly(ADP-ribose) levels but do not affect diethylnitrosamine-induced altered hepatic foci in Fischer-344 rats. *J Nutr* **125**: 1455–1461.
- Jager S, Handschin C, St-Pierre J, Spiegelman BM. 2007. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1 α . *Proc Natl Acad Sci* **104**: 12017–12022.
- Jin L, Galonek H, Israelian K, Choy W, Morrison M, Xia Y, Wang X, Xu Y, Yang Y, Smith JJ, et al. 2009. Biochemical characterization, localization, and tissue distribution of the longer form of mouse SIRT3. *Protein Sci* **18**: 514–525.
- Jing E, Gesta S, Kahn CR. 2007. SIRT2 regulates adipocyte differentiation through FoxO1 acetylation/deacetylation. *Cell Metab* **6**: 105–114.
- Kaerberlein M, McVey M, Guarente L. 1999. The SIR2/3/4 complex and SIR2 alone promote longevity in *Saccharomyces cerevisiae* by two different mechanisms. *Genes Dev* **13**: 2570–2580.
- Kamanna VS, Kashyap ML. 2008. Mechanism of action of niacin. *Am J Cardiol* **101**: 20B–26B.
- Karpe F, Frayn KN. 2004. The nicotinic acid receptor—A new mechanism for an old drug. *Lancet* **363**: 1892–1894.
- Kelly TJ, Lerin C, Haas W, Gygi SP, Puigserver P. 2009. GCN5-mediated transcriptional control of the metabolic coactivator PGC-1 β through lysine acetylation. *J Biol Chem* **284**: 19945–19952.
- Kirkland JB. 2009. Niacin status, NAD distribution and ADP-ribose metabolism. *Curr Pharm Des* **15**: 3–11.
- Krishnakumar R, Kraus WL. 2010. The PARP side of the nucleus: Molecular actions, physiological outcomes, and clinical targets. *Mol Cell* **39**: 8–24.
- Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, et al. 2006. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1 α . *Cell* **127**: 1109–1122.
- Lee HC. 2006. Structure and enzymatic functions of human CD38. *Mol Med* **12**: 317–323.
- Li X, Millar JS, Brownell N, Briand F, Rader DJ. 2010. Modulation of HDL metabolism by the niacin receptor GPR109A in mouse hepatocytes. *Biochem Pharmacol* **80**: 1450–1457.
- Lin SJ, Kaerberlein M, Andalis AA, Sturtz LA, Defossez PA, Culotta VC, Fink GR, Guarente L. 2002. Calorie restriction extends *Saccharomyces cerevisiae* lifespan by increasing respiration. *Nature* **418**: 344–348.
- Liszt G, Ford E, Kurtev M, Guarente L. 2005. Mouse Sir2 homolog SIRT6 is a nuclear ADP-ribosyltransferase. *J Biol Chem* **280**: 21313–21320.
- Mangerich A, Herbach N, Hanf B, Fischbach A, Popp O, Moreno-Villanueva M, Bruns OT, Burkle A. 2010. Inflammatory and age-related pathologies in mice with ectopic expression of human PARP-1. *Mech Ageing Dev* **131**: 389–404.
- Mendoza-Alvarez H, Alvarez-Gonzalez R. 1993. Poly(ADP-ribose) polymerase is a catalytic dimer and the automodification reaction is intermolecular. *J Biol Chem* **268**: 22575–22580.
- Michan S, Sinclair D. 2007. Sirtuins in mammals: Insights into their biological function. *Biochem J* **404**: 1–13.
- Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I. 2005. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. *Mol Biol Cell* **16**: 4623–4635.
- Nakagawa T, Lomb DJ, Haigis MC, Guarente L. 2009. SIRT5 deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. *Cell* **137**: 560–570.
- North BJ, Marshall BL, Borra MT, Denu JM, Verdin E. 2003. The human Sir2 ortholog, SIRT2, is an NAD⁺-dependent tubulin deacetylase. *Mol Cell* **11**: 437–444.
- Onyango P, Celic I, McCaffery JM, Boeke JD, Feinberg AP. 2002. SIRT3, a human SIR2 homologue, is an NAD-dependent deacetylase localized to mitochondria. *Proc Natl Acad Sci* **99**: 13653–13658.
- O'Reilly T, Niven DF. 2003. Levels of nicotinamide adenine dinucleotide in extracellular body fluids of pigs may be growth-limiting for *Actinobacillus pleuropneumoniae* and *Haemophilus parasuis*. *Can J Vet Res* **67**: 229–231.
- Pacholec M, Bleasdale JE, Chrnyk B, Cunningham D, Flynn D, Garofalo RS, Griffith D, Griffor M, Loulakis P, Pabst B, et al. 2010. SIRT1720, SIRT2183, SIRT1460, and resveratrol are not direct activators of SIRT1. *J Biol Chem* **285**: 8340–8351.
- Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong T, Machado De Oliveira R, Leid M, McBurney MW, Guarente L. 2004. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR- γ . *Nature* **429**: 771–776.
- Pillai JB, Isbatan A, Imai S, Gupta MP. 2005. Poly(ADP-ribose) polymerase-1-dependent cardiac myocyte cell death during heart failure is mediated by NAD⁺ depletion and reduced Sir2 α deacetylase activity. *J Biol Chem* **280**: 43121–43130.
- Pittelli M, Formentini L, Faraco G, Lapucci A, Rapizzi E, Cialdai F, Romano G, Moneti G, Moroni F, Chiarugi A. 2010. Inhibition of nicotinamide phosphoribosyltransferase: Cellular bioenergetics reveals a mitochondrial insensitive NAD pool. *J Biol Chem* **285**: 34106–34114.
- Revollo JR, Grimm AA, Imai S. 2004. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. *J Biol Chem* **279**: 50754–50763.
- Revollo JR, Korner A, Mills KF, Satoh A, Wang T, Garten A, Dasgupta B, Sasaki Y, Wolberger C, Townsend RR, et al. 2007. Nampt/PBEF/Visfatin regulates insulin secretion in β cells as a systemic NAD biosynthetic enzyme. *Cell Metab* **6**: 363–375.
- Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. 2005. Nutrient control of glucose homeostasis through a complex of PGC-1 α and SIRT1. *Nature* **434**: 113–118.
- Rongvaux A, Andris F, Van Gool F, Leo O. 2003. Reconstructing eukaryotic NAD metabolism. *Bioessays* **25**: 683–690.
- Rongvaux A, Galli M, Denanglaire S, Van Gool F, Dreze PL, Szpirer C, Bureau F, Andris F, Leo O. 2008. Nicotinamide phosphoribosyl transferase/pre-B cell colony-enhancing factor/visfatin is required for lymphocyte development and cellular resistance to genotoxic stress. *J Immunol* **181**: 4685–4695.
- Sauve AA. 2008. NAD⁺ and vitamin B3: From metabolism to therapies. *J Pharmacol Exp Ther* **324**: 883–893.
- Sauve AA, Wolberger C, Schramm VL, Boeke JD. 2006. The biochemistry of sirtuins. *Annu Rev Biochem* **75**: 435–465.
- Schwer B, North BJ, Frye RA, Ott M, Verdin E. 2002. The human silent information regulator (Sir)2 homologue hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase. *J Cell Biol* **158**: 647–657.
- Shi T, Wang F, Stieren E, Tong Q. 2005. SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes. *J Biol Chem* **280**: 13560–13567.
- Shieh WM, Ame JC, Wilson MV, Wang ZQ, Koh DW, Jacobson MK, Jacobson EL. 1998. Poly(ADP-ribose) polymerase null mouse cells synthesize ADP-ribose polymers. *J Biol Chem* **273**: 30069–30072.

- Skidmore CJ, Davies MI, Goodwin PM, Halldorsson H, Lewis PJ, Shall S, Zia'ee AA. 1979. The involvement of poly(ADP-ribose) polymerase in the degradation of NAD caused by gamma-radiation and *N*-methyl-*N*-nitrosourea. *Eur J Biochem* **101**: 135–142.
- Smith BC, Hallows WC, Denu JM. 2009. A continuous microplate assay for sirtuins and nicotinamide-producing enzymes. *Anal Biochem* **394**: 101–109.
- Tanno M, Sakamoto J, Miura T, Shimamoto K, Horio Y. 2007. Nucleocytoplasmic shuttling of the NAD⁺-dependent histone deacetylase SIRT1. *J Biol Chem* **282**: 6823–6832.
- Tischler ME, Friedrichs D, Coll K, Williamson JR. 1977. Pyridine nucleotide distributions and enzyme mass action ratios in hepatocytes from fed and starved rats. *Arch Biochem Biophys* **184**: 222–236.
- Tunaru S, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K, Offermanns S. 2003. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. *Nat Med* **9**: 352–355.
- Vaccari CS, Nagamia S, Thoenes M, Oguchi A, Hammoud R, Khan BV. 2007. Efficacy of controlled-release niacin in treatment of metabolic syndrome: Correlation to surrogate markers of atherosclerosis, vascular reactivity, and inflammation. *J Clin Lipidol* **1**: 605–613.
- Vakhrusheva O, Smolka C, Gajawada P, Kostin S, Boettger T, Kubin T, Braun T, Bober E. 2008. Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice. *Circ Res* **102**: 703–710.
- van der Veer E, Nong Z, O'Neil C, Urquhart B, Freeman D, Pickering JG. 2005. Pre-B-cell colony-enhancing factor regulates NAD⁺-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation. *Circ Res* **97**: 25–34.
- van der Veer E, Ho C, O'Neil C, Barbosa N, Scott R, Cregan SP, Pickering JG. 2007. Extension of human cell lifespan by nicotinamide phosphoribosyltransferase. *J Biol Chem* **282**: 10841–10845.
- van Roermund CW, Elgersma Y, Singh N, Wanders RJ, Tabak HF. 1995. The membrane of peroxisomes in *Saccharomyces cerevisiae* is impermeable to NAD(H) and acetyl-CoA under in vivo conditions. *EMBO J* **14**: 3480–3486.
- Vaquero A, Scher MB, Lee DH, Sutton A, Cheng HL, Alt FW, Serrano L, Sternglanz R, Reinberg D. 2006. SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis. *Genes Dev* **20**: 1256–1261.
- Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, Guarente L, Weinberg RA. 2001. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. *Cell* **107**: 149–159.
- Verdin E, Hirschey MD, Finley LW, Haigis MC. 2010. Sirtuin regulation of mitochondria: Energy production, apoptosis, and signaling. *Trends Biochem Sci* **35**: 669–675.
- Walker AK, Yang F, Jiang K, Ji JY, Watts JL, Purushotham A, Boss O, Hirsch ML, Ribich S, Smith JJ, et al. 2010. Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP. *Genes Dev* **24**: 1403–1417.
- Westphal S, Borucki K, Taneva E, Makarova R, Luley C. 2007. Extended-release niacin raises adiponectin and leptin. *Atherosclerosis* **193**: 361–365.
- Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, Tatar M, Sinclair D. 2004. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. *Nature* **430**: 686–689.
- Yamada K, Hara N, Shibata T, Osago H, Tsuchiya M. 2006. The simultaneous measurement of nicotinamide adenine dinucleotide and related compounds by liquid chromatography/electrospray ionization tandem mass spectrometry. *Anal Biochem* **352**: 282–285.
- Yamamoto H, Schoonjans K, Auwerx J. 2007. Sirtuin functions in health and disease. *Mol Endocrinol* **21**: 1745–1755.
- Yang H, Yang T, Baur JA, Perez E, Matsui T, Carmona JJ, Lamming DW, Souza-Pinto NC, Bohr VA, Rosenzweig A, et al. 2007a. Nutrient-sensitive mitochondrial NAD⁺ levels dictate cell survival. *Cell* **130**: 1095–1107.
- Yang T, Chan NY, Sauve AA. 2007b. Syntheses of nicotinamide riboside and derivatives: Effective agents for increasing nicotinamide adenine dinucleotide concentrations in mammalian cells. *J Med Chem* **50**: 6458–6461.

Cold Spring Harbor Symposia on Quantitative Biology

NAD⁺ as a Signaling Molecule Modulating Metabolism

C. Cantó and J. Auwerx

Cold Spring Harb Symp Quant Biol 2011 76: 291-298 originally published online February 17, 2012

Access the most recent version at doi:[10.1101/sqb.2012.76.010439](https://doi.org/10.1101/sqb.2012.76.010439)

References

This article cites 97 articles, 34 of which can be accessed free at:
<http://symposium.cshlp.org/content/76/291.full.html#ref-list-1>

License

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

To subscribe to *Cold Spring Harbor Symposia on Quantitative Biology* go to:
<http://symposium.cshlp.org/subscriptions>